Analgesic Prescribing in Patients with Inflammatory Arthritis in England: Observational Studies in the Clinical Practice Research Datalink

Overview

Journal Rheumatology (Oxford)

Publisher Oxford University Press

Specialty Rheumatology

Date 2023 Oct 11

PMID 37822018

Authors

Ian C Scott

Rebecca Whittle

James Bailey

Helen Twohig

Samantha L Hider

Christian D Mallen

Sara Muller

Kelvin P Jordan

Affiliations

Soon will be listed here.

Abstract

Objectives: Despite little evidence that analgesics are effective in inflammatory arthritis (IA), studies report substantial opioid prescribing. The extent this applies to other analgesics is uncertain. We undertook a comprehensive evaluation of analgesic prescribing in patients with IA in the Clinical Practice Research Datalink Aurum to evaluate this.

Methods: From 2004 to 2020, cross-sectional analyses evaluated analgesic prescription annual prevalence in RA, PsA and axial spondyloarthritis (axSpA), stratified by age, sex, ethnicity, deprivation and geography. Joinpoint regression evaluated temporal prescribing trends. Cohort studies determined prognostic factors at diagnosis for chronic analgesic prescriptions using Cox proportional hazards models.

Results: Analgesic prescribing declined over time but remained common: 2004 and 2020 IA prescription prevalence was 84.2/100 person-years (PY) (95% CI 83.9, 84.5) and 64.5/100 PY (64.2, 64.8), respectively. In 2004, NSAIDs were most prescribed (56.1/100 PY; 55.8, 56.5), falling over time. Opioids were most prescribed in 2020 (39.0/100 PY; 38.7, 39.2). Gabapentinoid prescribing increased: 2004 prevalence 1.1/100 PY (1.0, 1.2); 2020 prevalence 9.9/100 PY (9.7, 10.0). Most opioid prescriptions were chronic (2020 prevalence 23.4/100 PY [23.2, 23.6]). Non-NSAID analgesic prescribing was commoner in RA, older people, females and deprived areas/northern England. Conversely, NSAID prescribing was commoner in axSpA/males, varying little by deprivation/geography. Peri-diagnosis was high-risk for starting chronic opioid/NSAID prescriptions. Prognostic factors for chronic opioid/gabapentinoid and NSAID prescriptions differed, with NSAIDs having no consistently significant association with deprivation (unlike opioids/gabapentinoids).

Conclusion: IA analgesic prescribing of all classes is widespread. This is neither evidence-based nor in line with guidelines. Peri-diagnosis is an opportune moment to reduce chronic analgesic prescribing.

Citing Articles

Pharmacological pain management in patients with rheumatoid arthritis: a narrative literature review.

Cox N, Mallen C, Scott I BMC Med. 2025; 23(1):54.

PMID: 39881356 PMC: 11780779. DOI: 10.1186/s12916-025-03870-0.

Gabapentinoid use and the risk of fractures in patients with inflammatory arthritis: nested case-control study in the Clinical Practice Research Datalink Aurum.

Scott I, Daud N, Bailey J, Twohig H, Hider S, Mallen C BMC Med. 2024; 22(1):575.

PMID: 39663522 PMC: 11636031. DOI: 10.1186/s12916-024-03774-5.

Pain management in people with inflammatory arthritis: British Society for Rheumatology guideline scope.

Scott I, Babatunde O, Barker C, Beesley R, Beesley R, Birkinshaw H Rheumatol Adv Pract. 2024; 8(4):rkae128.

PMID: 39563967 PMC: 11573413. DOI: 10.1093/rap/rkae128.

Changes in opioid prescribing during the COVID-19 pandemic in England: an interrupted time-series analysis in the OpenSAFELY-TTP cohort.

Schaffer A, Andrews C, Brown A, Croker R, Hulme W, Nab L Lancet Public Health. 2024; 9(7):e432-e442.

PMID: 38942555 PMC: 7616651. DOI: 10.1016/S2468-2667(24)00100-2.

References

Scott I, Bailey J, White C, Mallen C, Muller S . Analgesic prescribing in patients with inflammatory arthritis in England: an observational study using electronic healthcare record data. Rheumatology (Oxford). 2021; 61(8):3201-3211. PMC: 9348777. DOI: 10.1093/rheumatology/keab870. View

Karmali R, Bush C, Raman S, Campbell C, Skinner A, Roberts A . Long-term opioid therapy definitions and predictors: A systematic review. Pharmacoepidemiol Drug Saf. 2019; 29(3):252-269. PMC: 7058495. DOI: 10.1002/pds.4929. View

Park S, Le T, Slejko J, Villalonga-Olives E, Onukwugha E . Changes in Opioid Utilization Following Tumor Necrosis Factor Inhibitor Initiation in Patients with Rheumatoid Arthritis. Rheumatol Ther. 2019; 6(4):611-616. PMC: 6858479. DOI: 10.1007/s40744-019-00175-6. View

Zeng C, Zhang W, Doherty M, Persson M, Mallen C, Swain S . Initial analgesic prescriptions for osteoarthritis in the United Kingdom, 2000-2016. Rheumatology (Oxford). 2020; 60(1):147-159. DOI: 10.1093/rheumatology/keaa244. View

Stokes A, Berry K, Collins J, Hsiao C, Waggoner J, Johnston S . The contribution of obesity to prescription opioid use in the United States. Pain. 2019; 160(10):2255-2262. PMC: 6756256. DOI: 10.1097/j.pain.0000000000001612. View

Accortt N, Schenfeld J, Chang E, Papoyan E, Broder M . Changes in Healthcare Utilization After Etanercept Initiation in Patients with Rheumatoid Arthritis: A Retrospective Claims Analysis. Adv Ther. 2017; 34(9):2093-2103. PMC: 5599457. DOI: 10.1007/s12325-017-0596-6. View

Serdarevic M, Striley C, Cottler L . Sex differences in prescription opioid use. Curr Opin Psychiatry. 2017; 30(4):238-246. PMC: 5675036. DOI: 10.1097/YCO.0000000000000337. View

Sloan V, Sheahan A, Stark J, Suruki R . Opioid Use in Patients with Ankylosing Spondylitis Is Common in the United States: Outcomes of a Retrospective Cohort Study. J Rheumatol. 2019; 46(11):1450-1457. DOI: 10.3899/jrheum.180972. View

Geenen R, Overman C, Christensen R, Asenlof P, Capela S, Huisinga K . EULAR recommendations for the health professional's approach to pain management in inflammatory arthritis and osteoarthritis. Ann Rheum Dis. 2018; 77(6):797-807. DOI: 10.1136/annrheumdis-2017-212662. View

10.

Mooney J, Yau R, Moiz H, Kidy F, Evans A, Hillman S . Associations between socioeconomic deprivation and pharmaceutical prescribing in primary care in England. Postgrad Med J. 2020; 98(1157):193-198. DOI: 10.1136/postgradmedj-2020-138944. View

11.

Chou R, Turner J, Devine E, Hansen R, Sullivan S, Blazina I . The effectiveness and risks of long-term opioid therapy for chronic pain: a systematic review for a National Institutes of Health Pathways to Prevention Workshop. Ann Intern Med. 2015; 162(4):276-86. DOI: 10.7326/M14-2559. View

12.

Bedson J, Chen Y, Hayward R, Ashworth J, Walters K, Dunn K . Trends in long-term opioid prescribing in primary care patients with musculoskeletal conditions: an observational database study. Pain. 2016; 157(7):1525-1531. PMC: 4912234. DOI: 10.1097/j.pain.0000000000000557. View

13.

Scott I, Whittle R, Bailey J, Twohig H, Hider S, Mallen C . Rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis epidemiology in England from 2004 to 2020: An observational study using primary care electronic health record data. Lancet Reg Health Eur. 2022; 23:100519. PMC: 9557034. DOI: 10.1016/j.lanepe.2022.100519. View

14.

Crossfield S, Buch M, Baxter P, Kingsbury S, Pujades-Rodriguez M, Conaghan P . Changes in the pharmacological management of rheumatoid arthritis over two decades. Rheumatology (Oxford). 2021; 60(9):4141-4151. PMC: 8409998. DOI: 10.1093/rheumatology/keaa892. View

15.

Loft N, Nguyen T, Kristensen L, Thyssen J, Egeberg A . Disease burden, symptoms, and use of analgesics in patients with psoriasis with or without psoriatic arthritis: A cross-sectional study. J Am Acad Dermatol. 2021; 86(3):590-597. DOI: 10.1016/j.jaad.2021.07.028. View

16.

Curtis J, Xie F, Smith C, Saag K, Chen L, Beukelman T . Changing Trends in Opioid Use Among Patients With Rheumatoid Arthritis in the United States. Arthritis Rheumatol. 2017; 69(9):1733-1740. DOI: 10.1002/art.40152. View

17.

Jobski K, Luque Ramos A, Albrecht K, Hoffmann F . Pain, depressive symptoms and medication in German patients with rheumatoid arthritis-results from the linking patient-reported outcomes with claims data for health services research in rheumatology (PROCLAIR) study. Pharmacoepidemiol Drug Saf. 2017; 26(7):766-774. DOI: 10.1002/pds.4202. View

18.

Kroon F, van der Burg L, Ramiro S, Landewe R, Buchbinder R, Falzon L . Non-steroidal anti-inflammatory drugs (NSAIDs) for axial spondyloarthritis (ankylosing spondylitis and non-radiographic axial spondyloarthritis). Cochrane Database Syst Rev. 2015; (7):CD010952. PMC: 8942090. DOI: 10.1002/14651858.CD010952.pub2. View

19.

Keystone E, Kavanaugh A, Sharp J, Tannenbaum H, Hua Y, Teoh L . Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized,.... Arthritis Rheum. 2004; 50(5):1400-11. DOI: 10.1002/art.20217. View

20.

Hunter T, Nguyen C, Birt J, Smith J, Shan M, Tan H . Pain Medication and Corticosteroid Use in Ankylosing Spondylitis, Psoriatic Arthritis, and Rheumatoid Arthritis in the United States: A Retrospective Observational Study. Rheumatol Ther. 2021; 8(3):1371-1382. PMC: 8380595. DOI: 10.1007/s40744-021-00344-6. View